Previous 10 |
home / stock / sva:cc / sva:cc news
(TheNewswire) LONDON, ONTARIO – TheNewswire - May 9, 2022 – Sernova Corp. (TSXV:SVA) (OTC:SEOVF) (FSE/XETRA:PSH), a clinical-stage cell therapy therapeutics company focused on developing a potential ‘functional cure’ for type 1 diabetes (T1D...
(TheNewswire) Sernova Engages Leading U.S.-Based Healthcare Communications Firm to Broaden Awareness of Potential ‘Functional Cure’ Technology for Type 1 Diabetes LONDON, ONTARIO – TheNewswire - May 5, 2022 – Sernova Corp. (TSXV:SVA)...
(TheNewswire) LONDON, ONTARIO – TheNewswire - April 29, 2022 – Sernova Corp. (TSXV:SVA)(OTC:SEOVF)(FSE:PSH), a clinical stage regenerative medicine company focused on developing a potential ‘functional cure’ for type 1 diabetes (T1D) and...
(TheNewswire) Confirms Ongoing Safety and Tolerability of Sernova’s Cell Pouch LONDON, ONTARIO – TheNewswire - March 17, 2022 – Sernova Corp. (TSXV:SVA) (OTC:SEOVF) (FSE:PSH), a clinical- stage company and leader in regenerative medicine cell the...
News, Short Squeeze, Breakout and More Instantly...
(TheNewswire) LONDON, Ontario; BOSTON, Massachusetts – TheNewswire - July 15, 2024 – Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage biotechnology company focused on the development of regenerative medicine cell therapies for treatment o...
(TheNewswire) To date Sernova reports 7 patients in its Phase I/II type 1 diabetes clinical trial achieved freedom from insulin injections and demonstrate blood sugar control in the non- diabetic range (HbA1c 6.5%); 6 patients have reached between 5.5 and 50 months o...
(TheNewswire) LONDON, Ontario; BOSTON, Massachusetts – June 12, 2024 – TheNewswire – Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage biotechnology company focused on the development of regenerative medicine cell therapies for treatmen...